Bioheart, Inc. (OTCQB: BHRT) is an emerging enterprise in
the regenerative medicine industry focused on the discovery, development and
commercialization of cell-based therapeutics that prevent, treat or cure cardiovascular
diseases. The company’s leading product candidate is MyoCell®, a muscle stem
cell therapy that is intended to improve cardiac function in patients with
severe heart damage due to a heart attack. In January, Bioheart announced plans
to initiate phase III clinical studies of the candidate for the treatment of
chronic heart failure in the coming months. Currently, Bioheart is aiming to
achieve market approval for MyoCell in 2019.
According to the American Heart Association, approximately
4.9 million Americans are currently living with congestive heart failure,
demonstrating the immense market potential for Bioheart’s primary product
candidate moving forward. Using muscle stem cells known as myoblasts, MyoCell
therapy addresses cardiovascular damage by promoting increased muscle formation
in patients’ hearts. In clinical studies, these unique cells have survived in
the low-oxygen environment of chronically damaged, scarred heart tissue better
than any other cell type, and they can be genetically modified to attract the
stem cells of patients in order to assist with the regenerative process.
In addition to the development of cell-based therapeutics,
Bioheart promotes revenue through physician and patient-based regenerative
medicine training services, cell collection and cell storage services, the sale
of cell collection and treatment kits for humans and animals and the operation
of a cell therapy clinic. In the first quarter of 2015, the company leveraged
these products and services to realize an increase in year-over-year revenues
of nearly 25 percent, recording $490,000 for the period. In the future,
Bioheart’s management team expects these revenue-generating operations to
provide necessary funding to support the company’s clinical development activities,
as well as general business expenses.
“We continue to advance on our plan and pathway to
profitability,” Mike Tomas, president and chief executive officer of Bioheart,
stated in a news release. “We remain confident in our abilities and steadfast
on our objectives and desire to create positive outcomes for our patients and
positive investment outcomes for our shareholders.”
For prospective shareholders, Bioheart represents an
intriguing investment opportunity. The company’s unique combination of promising
therapeutic candidates and revenue-generating capabilities could provide it
with a platform upon which to realize sustainable growth in market share and
improved financial results in the years to come.
For more information, visit www.bioheartinc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment